Mitsubishi UFJ Asset Management Co. Ltd. Purchases New Shares in IQVIA Holdings Inc. $IQV

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 406,318 shares of the medical research company’s stock, valued at approximately $78,509,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Brighton Jones LLC boosted its holdings in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares in the last quarter. Empowered Funds LLC increased its stake in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after acquiring an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in IQVIA during the 2nd quarter valued at about $514,000. First Trust Advisors LP boosted its stake in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after acquiring an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after purchasing an additional 1,155 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on IQV shares. Barclays restated an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. TD Cowen boosted their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Stifel Nicolaus increased their target price on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Mizuho lifted their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Stock Performance

IQV stock opened at $240.25 on Wednesday. The stock’s 50 day simple moving average is $208.88 and its 200 day simple moving average is $186.72. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The stock has a market capitalization of $39.54 billion, a PE ratio of 29.81, a price-to-earnings-growth ratio of 2.01 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider W Richard Staub sold 5,500 shares of IQVIA stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,913 shares of company stock valued at $3,098,793 over the last quarter. Corporate insiders own 1.70% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.